{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative+Metastatic+Breast+Cancer&page=2", "query": { "condition": "Triple Negative Metastatic Breast Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative+Metastatic+Breast+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T07:30:38.088Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04177108", "title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo for Atezolizumab", "type": "DRUG" }, { "name": "Placebo for Ipatasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2019-11-25", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 31, "location_summary": "Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04177108" }, { "nct_id": "NCT04348747", "title": "Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Anti-HER2/HER3 Dendritic Cell Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 23, "start_date": "2022-12-19", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 3, "location_summary": "Tampa, Florida • Buffalo, New York • Charlottesville, Virginia", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04348747" }, { "nct_id": "NCT05035407", "title": "T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kita-kyushu Lung Cancer Antigen 1, Human" ], "interventions": [ { "name": "IL-2 (Aldesleukin)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "KK-LC-1 TCR", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CXR", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Meperidine", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2022-03-08", "completion_date": "2025-07-16", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05035407" }, { "nct_id": "NCT06682793", "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Non-Small Cell Lung", "NSCLC (Non-small Cell Lung Cancer)", "Cancer", "Colon Cancer", "Rectal Cancer", "Lung Cancer", "CRC", "Head and Neck Squamous Cell Cancer", "HNSCC", "Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Triple Negative Breast Cancer", "TNBC", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "A2B395", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2025-05-22", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 10, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682793" }, { "nct_id": "NCT01031446", "title": "Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2009-10", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 4, "location_summary": "Chattanooga, Tennessee • Jackson, Tennessee • Knoxville, Tennessee + 1 more", "locations": [ { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031446" }, { "nct_id": "NCT05967533", "title": "The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Renal Cell Carcinoma", "Advanced Triple-Negative Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer (AJCC) v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Fermented Wheat Germ Extract", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-06-02", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05967533" }, { "nct_id": "NCT06545331", "title": "Study of XB010 in Subjects With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "Esophageal Squamous Cell Cancer", "Head and Neck Squamous Cell Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Hormone-receptor-positive Breast Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "XB010", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2024-08-06", "completion_date": "2027-10-20", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 15, "location_summary": "Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545331" }, { "nct_id": "NCT04348916", "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Melanoma", "Solid Tumor", "Squamous Cell Carcinoma of Head and Neck", "Breast Cancer", "Advanced Solid Tumor", "Triple Negative Breast Cancer", "Colorectal Carcinoma", "Non-melanoma Skin Cancer", "Liver Metastases" ], "interventions": [ { "name": "ONCR-177", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oncorus, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2020-05-20", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 10, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04348916" }, { "nct_id": "NCT07115043", "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma (Skin)", "Renal Cell Carcinoma", "Merkel Cell Carcinoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Gastric Cancer/Gastroesophageal Junction Cancer", "High Grade Serous Ovarian Carcinoma" ], "interventions": [ { "name": "AZD6750", "type": "DRUG" }, { "name": "rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-07-29", "completion_date": "2029-10-02", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 6, "location_summary": "Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115043" }, { "nct_id": "NCT05958199", "title": "A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm" ], "interventions": [ { "name": "NPX267", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextPoint Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2023-07-21", "completion_date": "2025-09-20", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-06-10T07:30:38.088Z", "location_count": 7, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 4 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05958199" } ] }